| Title |
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
|
|---|---|
| Published in |
BMC Cancer, July 2014
|
| DOI | 10.1186/1471-2407-14-508 |
| Pubmed ID | |
| Authors |
Motoyasu Kato, Takehito Shukuya, Fumiyuki Takahashi, Keita Mori, Kentaro Suina, Tetsuhiko Asao, Ryota Kanemaru, Yuichiro Honma, Keiko Muraki, Koji Sugano, Rina Shibayama, Ryo Koyama, Naoko Shimada, Kazuhisa Takahashi |
| Abstract |
Non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) need to be approached carefully given the high incidence of pulmonary toxicity. Pemetrexed (PEM) is the key drug for the treatment of NSCLC. However, its safety, especially with respect to the exacerbation of ILD, and efficacy in NSCLC patients with ILD have yet to be established. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sao Tome and Principe | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 5 | 21% |
| Researcher | 3 | 13% |
| Other | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 9 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 50% |
| Sports and Recreations | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Economics, Econometrics and Finance | 1 | 4% |
| Unknown | 9 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2014.
All research outputs
#15,313,289
of 22,775,504 outputs
Outputs from BMC Cancer
#4,104
of 8,286 outputs
Outputs of similar age
#131,400
of 225,832 outputs
Outputs of similar age from BMC Cancer
#62
of 137 outputs
Altmetric has tracked 22,775,504 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,286 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,832 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.